Microvascular outcomes in type 2 diabetes – Authors' reply

Sophia Zoungas; Hertzel C. Gerstein; Rury R. Holman; Peter Reaven; Mark Woodward; Hisatomi Arima; Ruth L. Coleman; John Chalmers; Collaborators on Trials of Lowering Glucose (CONTROL) writing group

doi:10.1016/S2213-8587(17)30185-7

Microvascular outcomes in type 2 diabetes – Authors' reply

Sophia Zoungas, Hertzel C. Gerstein, Rury R. Holman, Peter Reaven, Mark Woodward, Hisatomi Arima, Ruth L. Coleman, John Chalmers, Collaborators on Trials of Lowering Glucose (CONTROL) writing group

Research output: Contribution to journal › Letter › peer-review

Abstract

We appreciate Coen Stehouwer and Thomas van Sloten's comments on the clinical relevance of the endpoints in our meta-analysis of individual participant data from the four large trials of more versus less intensive glucose control in patients with type 2 diabetes. The selection of endpoints followed a rigorous, prespecified process that included foremost: consideration of clinical relevance, use of common definitions, standardised ascertainment, and data availability across the trials.

Original language	English
Pages (from-to)	580
Number of pages	1
Journal	The Lancet Diabetes and Endocrinology
Volume	5
Issue number	8
DOIs	https://doi.org/10.1016/S2213-8587(17)30185-7
Publication status	Published - Aug 2017
Externally published	Yes

Keywords

Correspondence
reply
response
type 2 diabetes
Microvascular outcomes
less intensive glucose control
selection of endpoints
composite endpoints
macroalbuminuria
retinopathy

Access to Document

10.1016/S2213-8587(17)30185-7Licence: In Copyright

Cite this

@article{338f8ec48708495d850ff1f41e7be2e9,

title = "Microvascular outcomes in type 2 diabetes – Authors' reply",

abstract = "We appreciate Coen Stehouwer and Thomas van Sloten's comments on the clinical relevance of the endpoints in our meta-analysis of individual participant data from the four large trials of more versus less intensive glucose control in patients with type 2 diabetes. The selection of endpoints followed a rigorous, prespecified process that included foremost: consideration of clinical relevance, use of common definitions, standardised ascertainment, and data availability across the trials.",

keywords = "Correspondence, reply, response, type 2 diabetes, Microvascular outcomes, less intensive glucose control, selection of endpoints, composite endpoints, macroalbuminuria, retinopathy",

author = "Sophia Zoungas and Gerstein, {Hertzel C.} and Holman, {Rury R.} and Peter Reaven and Mark Woodward and Hisatomi Arima and Coleman, {Ruth L.} and John Chalmers and {Collaborators on Trials of Lowering Glucose (CONTROL) writing group}",

year = "2017",

month = aug,

doi = "10.1016/S2213-8587(17)30185-7",

language = "English",

volume = "5",

pages = "580",

journal = "The Lancet Diabetes and Endocrinology",

issn = "2213-8587",

publisher = "NA",

number = "8",

}

TY - JOUR

T1 - Microvascular outcomes in type 2 diabetes – Authors' reply

AU - Zoungas, Sophia

AU - Gerstein, Hertzel C.

AU - Holman, Rury R.

AU - Reaven, Peter

AU - Woodward, Mark

AU - Arima, Hisatomi

AU - Coleman, Ruth L.

AU - Chalmers, John

AU - Collaborators on Trials of Lowering Glucose (CONTROL) writing group

PY - 2017/8

Y1 - 2017/8

N2 - We appreciate Coen Stehouwer and Thomas van Sloten's comments on the clinical relevance of the endpoints in our meta-analysis of individual participant data from the four large trials of more versus less intensive glucose control in patients with type 2 diabetes. The selection of endpoints followed a rigorous, prespecified process that included foremost: consideration of clinical relevance, use of common definitions, standardised ascertainment, and data availability across the trials.

AB - We appreciate Coen Stehouwer and Thomas van Sloten's comments on the clinical relevance of the endpoints in our meta-analysis of individual participant data from the four large trials of more versus less intensive glucose control in patients with type 2 diabetes. The selection of endpoints followed a rigorous, prespecified process that included foremost: consideration of clinical relevance, use of common definitions, standardised ascertainment, and data availability across the trials.

KW - Correspondence

KW - reply

KW - response

KW - type 2 diabetes

KW - Microvascular outcomes

KW - less intensive glucose control

KW - selection of endpoints

KW - composite endpoints

KW - macroalbuminuria

KW - retinopathy

UR - http://www.scopus.com/inward/record.url?scp=85024874391&partnerID=8YFLogxK

U2 - 10.1016/S2213-8587(17)30185-7

DO - 10.1016/S2213-8587(17)30185-7

M3 - Letter

C2 - 28732664

AN - SCOPUS:85024874391

VL - 5

SP - 580

JO - The Lancet Diabetes and Endocrinology

JF - The Lancet Diabetes and Endocrinology

SN - 2213-8587

IS - 8

ER -

Microvascular outcomes in type 2 diabetes – Authors' reply

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this